1. Market Research
  2. > Blood Coagulation - Pipeline Review, H1 2013

Blood Coagulation - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 58 pages

Blood Coagulation - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Blood Coagulation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Blood Coagulation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Coagulation. Blood Coagulation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Blood Coagulation.
- A review of the Blood Coagulation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Blood Coagulation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Blood Coagulation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Blood Coagulation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Blood Coagulation - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Blood Coagulation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Blood Coagulation 7
Blood Coagulation Therapeutics under Development by Companies 9
Blood Coagulation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Blood Coagulation Therapeutics - Products under Development by Companies 14
Blood Coagulation Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Blood Coagulation Therapeutics Development 16
Bayer AG 16
Endotis Pharma 17
ARCA biopharma, Inc. 18
China Biologic Products, Inc. 19
PepTx, Inc. 20
Blood Coagulation - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
rivaroxaban - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
fondaparinux sodium - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
NU-172 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Human Prothrombin Complex Concentrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
PTX-003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
NAVOH-002 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
DIS-COM-COAG - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Recombinant Simukunin - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Vicagrel - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Factor XIa Inhibitors - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Blood Coagulation Therapeutics - Drug Profile Updates 40
Blood Coagulation Therapeutics - Dormant Products 51
Blood Coagulation - Product Development Milestones 52
Featured News and Press Releases 52
Mar 27, 2013: Pozen Submits New Drug Application For PA32540 52
Oct 31, 2012: Asahi Kasei Pharma America Initiates Phase III Clinical Trial For ART-123 In Severe Sepsis Patients With Coagulopathy 53
Jul 04, 2012: Platelet Drug Shows Clinical Benefits For Severe, Unresponsive Aplastic Anemia 53
Feb 28, 2012: Thrombotech Receives FDA Approval For Phase IIa Trial Of THR-18 In US 54
Jun 29, 2011: Kyowa Hakko Kirin Initiates Phase III Clinical Study Of KW-3357 In Japan 54
Nov 15, 2010: Portola Announces Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity Of Factor Xa Inhibitors 55
Apr 29, 2010: Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase IIb Study Of ART-123 In Sepsis Patients With DIC 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables


Number of Products Under Development for Blood Coagulation, H1 2013 7
Products under Development for Blood Coagulation - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Bayer AG, H1 2013 16
Endotis Pharma, H1 2013 17
ARCA biopharma, Inc., H1 2013 18
China Biologic Products, Inc., H1 2013 19
PepTx, Inc., H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Blood Coagulation Therapeutics - Drug Profile Updates 40
Blood Coagulation Therapeutics - Dormant Products 51

List of Figures


Number of Products under Development for Blood Coagulation, H1 2013 7
Products under Development for Blood Coagulation - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Discovery and Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.